

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**  
**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**Date of Report (Date of earliest event reported): November 3, 2003**

**OraSure Technologies, Inc.**  
(Exact name of issuer as specified in charter)

**DELAWARE**  
(State or Other Jurisdiction  
of Incorporation or  
Organization)

**001-16537**  
(Commission  
file  
number)

**36-4370966**  
(I.R.S. Employer  
Identification  
Number)

**220 East First Street**  
**Bethlehem, Pennsylvania 18015-1360**  
(Address of principal executive offices)

**(610) 882-1820**  
(Registrant's telephone number, including area code)

---

**Item 5—Other Events and Regulation FD Disclosure.**Underwriters Exercise Over-Allotment Option.

OraSure Technologies, Inc. (the “Company”) issued a press release on November 3, 2003, announcing that the underwriters of its recent public offering of 5,000,000 shares of common stock have purchased an additional 311,000 shares of its common stock pursuant to an over-allotment option granted in connection with the offering. This represents a partial exercise of the option, which originally covered 750,000 shares of common stock. Thomas Weisel Partners LLC has acted as the lead underwriter and SG Cowen Securities Corporation and Wells Fargo Securities, LLC have acted as co-managers in this transaction. The information contained in the press release dated November 3, 2003 is incorporated herein by reference and attached to this Current Report on Form 8-K as Exhibit 99.

**Item 7. Financial Statements and Exhibits**

## (c) Exhibits

<u>Exhibit Number</u>	<u>Description</u>
99	Press Release dated November 3, 2003, announcing the exercise of the underwriters’ overallotment option in connection with the recent public offering of common stock by OraSure Technologies, Inc.

## Signatures

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ORASURE TECHNOLOGIES, INC

Date: November 3, 2003

By: /s/ JACK E. JERRETT

---

**Jack E. Jerrett**  
**Senior Vice President, General Counsel**  
**and Secretary**

---

**Index to Exhibits**

**Exhibit Number**

**Description**

99

Press Release dated November 3, 2003, announcing the exercise of the underwriters' overallotment option in connection with the recent public offering of common stock by OraSure Technologies, Inc.



**OraSure Technologies, Inc.**

diagnostic solutions for the new millennium

Company Contact:

Ronald H. Spair  
Chief Financial Officer  
610-882-1820  
[Investorinfo@orasure.com](mailto:Investorinfo@orasure.com)  
[www.orasure.com](http://www.orasure.com)

**ORASURE ANNOUNCES EXERCISE OF UNDERWRITERS'  
OVERALLOTMENT OPTION**

**BETHLEHEM, PA** — November 3, 2003—OraSure Technologies, Inc. (Nasdaq NM:OSUR) today announced that the underwriters of its recent public offering of 5,000,000 shares of common stock have purchased an additional 311,000 shares pursuant to an overallotment option granted in connection with the offering. This represents a partial exercise of the option, which originally covered 750,000 shares of the Company's common stock. With the exercise of the overallotment option, the offering will have resulted in the sale of a total of 5,311,000 shares of common stock, with total proceeds to the Company, after underwriting discounts, of \$45,170,055.

OraSure intends to use the net proceeds from the offering for general working capital, commercialization of new products, research and development activities, potential acquisitions, capital expenditures, patent license fees, debt service and retirement, and general corporate purposes.

Thomas Weisel Partners LLC has acted as the lead underwriter, and SG Cowen Securities Corporation and Wells Fargo Securities, LLC have acted as co-managers in this transaction.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. This offering of common stock may be made only by means of a prospectus, a copy of which can be obtained from the offices of Thomas Weisel Partners LLC, 390 Park Avenue, New York, NY 10022. An electronic copy of the prospectus is available on the Securities and Exchange Commission web site at [www.sec.gov](http://www.sec.gov).

OraSure Technologies develops, manufactures and markets oral fluid specimen collection devices and tests and other diagnostic products using its proprietary technologies, including immunoassays and other *in vitro* diagnostic tests and other medical devices. These products are sold in the United States and certain foreign countries to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. For more information on the Company, please visit [www.orasure.com](http://www.orasure.com).

###